Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03846583
Title Tucatinib + Abemaciclib + Herceptin for HER2+ MBC
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

Her2-receptor positive breast cancer

Therapies

Abemaciclib + Trastuzumab + Tucatinib

Age Groups: adult | senior
Covered Countries


No variant requirements are available.